報價延遲最少15分鐘:2024/09/20 18:38 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.5 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-7.41/-5.55
|
|
企業價值
482.30M
|
| 資產負債 |
|
每股賬面淨值
10.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
86.46M
|
|
每股收益
18.24
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/09/20 18:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others. |